Cao Chao, Wang Ruixuan, Wang Xiangren, Abufaraj Mohammad, Waldhoer Thomas, Gotto Geoffrey T, Shariat Shahrokh F, Yang Lin
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Department of Health Service Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, FL 32611, USA.
Curr Oncol. 2025 Sep 5;32(9):498. doi: 10.3390/curroncol32090498.
To evaluate the prevalence and cancer-specific patterns of kidney stones among U.S. cancer survivors compared to non-cancer adults. This was a serial cross-sectional, descriptive epidemiologic analysis of a US nationally representative sample from the National Health and Nutrition Examination Survey from 2007 to 2020. Weighted prevalence of kidney stones was estimated for both non-cancer adults and cancer survivors by study cycle. Multivariable logistic regression was conducted to examine factors associated with higher probability of kidney stones in both non-cancer adults and cancer survivors. From 2007-2008 to 2017-2020, kidney stone prevalence rose in both non-cancer adults (8.5% to 9.2%, for trend = 0.013) and cancer survivors (13.1% to 17.3%, for trend = 0.033). Throughout the study period, prevalence was consistently higher in cancer survivors. The overall prevalence from 2007 to 2020 was 15.8% (95% CI: 14.0-17.5%) in cancer survivors and 9.2% (95% CI: 8.8-9.6%) in non-cancer adults. After adjusting for sociodemographic, lifestyle, and health factors, cancer survivors had higher odds of kidney stones (OR = 1.28, 95% CI: 1.10-1.49). Compared with non-cancer adults, survivors of ovarian (OR = 3.71, 95% CI: 1.77-7.78), kidney (OR = 2.88, 95% CI: 1.46-5.68), bone and soft tissue (OR = 2.86, 95% CI: 1.12-7.30), uterine (OR = 1.94, 95% CI: 1.17-3.22), cervix (OR = 1.68, 95% CI: 1.08-2.61) and prostate (OR = 1.41, 95% CI: 1.06-1.87) cancers were statistically more likely to report kidney stones. The prevalence was numerically highest among survivors of kidney cancer (34.7%), followed by bone and soft tissue (29.9%), ovarian (29.8%), and testicular (26.3%) cancers. The higher prevalence of kidney stones in cancer survivors, with substantial variation by cancer type, highlights the urgent need for effective clinical management of kidney stones in oncology settings and mechanistic research.
为评估美国癌症幸存者与非癌症成年人相比肾结石的患病率及癌症特异性模式。这是一项对2007年至2020年美国国家健康与营养检查调查中具有全国代表性样本的系列横断面描述性流行病学分析。按研究周期估算非癌症成年人和癌症幸存者肾结石的加权患病率。进行多变量逻辑回归以检查非癌症成年人和癌症幸存者中与肾结石发生概率较高相关的因素。从2007 - 2008年到2017 - 2020年，非癌症成年人（从8.5%升至9.2%，趋势P = 0.013）和癌症幸存者（从13.1%升至17.3%，趋势P = 0.033）的肾结石患病率均有所上升。在整个研究期间，癌症幸存者的患病率始终较高。2007年至2020年的总体患病率在癌症幸存者中为15.8%（95%置信区间：14.0 - 17.5%），在非癌症成年人中为9.2%（95%置信区间：8.8 - 9.6%）。在调整社会人口统计学、生活方式和健康因素后，癌症幸存者患肾结石的几率更高（比值比 = 1.28，95%置信区间：1.10 - 1.49）。与非癌症成年人相比，卵巢癌（比值比 = 3.71，95%置信区间：1.77 - 7.78）、肾癌（比值比 = 2.88，95%置信区间：1.46 - 5.68）、骨与软组织癌（比值比 = 2.86，95%置信区间：1.12 - 7.30）、子宫癌（比值比 = 1.94，95%置信区间：1.17 - 3.22）、宫颈癌（比值比 = 1.68，95%置信区间：1.08 - 2.61）和前列腺癌（比值比 = 1.41，95%置信区间：1.06 - 1.87）的幸存者报告患肾结石的统计学可能性更高。患病率在肾癌幸存者中数值最高（34.7%），其次是骨与软组织癌（29.9%）、卵巢癌（29.8%）和睾丸癌（26.3%）。癌症幸存者中肾结石患病率较高，且因癌症类型存在显著差异，这凸显了在肿瘤学环境中对肾结石进行有效临床管理和开展机制研究的迫切需求。
